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A B S T R A C T
Myocardial infarction (MI) leads to a multi-phase reparative process at the site of damaged heart that ultimately
results in the formation of non-conductive ﬁbrous scar tissue. Despite the widespread use of electroconductive
biomaterials to increase the physiological relevance of bioengineered cardiac tissues in vitro, there are still
several limitations associated with engineering biocompatible scaﬀolds with appropriate mechanical properties
and electroconductivity for cardiac tissue regeneration. Here, we introduce highly adhesive ﬁbrous scaﬀolds
engineered by electrospinning of gelatin methacryloyl (GelMA) followed by the conjugation of a choline-based
bio-ionic liquid (Bio-IL) to develop conductive and adhesive cardiopatches. These GelMA/Bio-IL adhesive pat-
ches were optimized to exhibit mechanical and conductive properties similar to the native myocardium.
Furthermore, the engineered patches strongly adhered to murine myocardium due to the formation of ionic
bonding between the Bio-IL and native tissue, eliminating the need for suturing. Co-cultures of primary cardi-
omyocytes and cardiac ﬁbroblasts grown on GelMA/Bio-IL patches exhibited comparatively better contractile
proﬁles compared to pristine GelMA controls, as demonstrated by over-expression of the gap junction protein
connexin 43. These cardiopatches could be used to provide mechanical support and restore electromechanical
coupling at the site of MI to minimize cardiac remodeling and preserve normal cardiac function.
1. Introduction
Coronary heart disease (CHD) remains one of the major causes of
death and disability in developed countries and accounts for approxi-
mately one third of all reported deaths in people older than 35 years of
age [1]. CHD often leads to partial or complete blockage of a coronary
artery due to the rupture of an atherosclerotic plaque, in an event
known as myocardial infarction (MI). MI severely restricts blood ﬂow to
the myocardium, which causes extensive cardiomyocyte (CM) death [2]
and triggers a cascade of remodeling mechanisms such as left ventricle
(LV) dilation, myocardium hypertrophy, and the appearance of ﬁbrous
and non-contractile scar tissue [3,4]. Cardiac remodeling has a pro-
found impact on both infarcted and non-infarcted regions of the heart,
which greatly impairs normal cardiac function and could lead to
chronic heart failure. Moreover, the formation of non-excitable and
non-contractile scar tissue leads to asynchronous heart beating, owing
to the interruption in the propagation of electrical impulses across the
myocardium [5–7]. In recent years, regenerative approaches based on
multipotent and pluripotent stem cell therapy have shown great pro-
mise both in vitro and in vivo, albeit with highly heterogeneous out-
comes and poor clinical translation [8,9]. Therefore, signiﬁcant eﬀorts
have been made towards the development of therapeutic strategies that
can provide support to the infarcted tissues and restore electro-
mechanical coupling at the site of MI. This in turn could help minimize
the formation of scar tissue and thus preserve normal cardiac function.
Cardiac tissue engineering (TE) has enabled the development of
temporary biomimetic scaﬀolds that can promote local cell growth and
organization [5]. These scaﬀolds are mainly aimed at providing me-
chanical support to the infarcted area, which minimizes cardiac re-
modeling and helps preserve the contractile function of the heart
[10–12]. However, the recapitulation of the morphological and phy-
siological features of the native myocardium remains challenging due
to the complexity of structural, biochemical, and biophysical properties
of the native cardiac microenvironment [13]. For instance, these
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scaﬀolds should exhibit high durability and mechanical resilience to
withstand repeated cycles of stretching during cardiac beating [14].
Moreover, the composition of these cardiac patches should be based on
biocompatible materials that can also be biodegraded in a clinically
relevant time frame. Recent advancements in the ﬁeld of material
chemistry and microfabrication have allowed the engineering of a
variety of cell-laden and acellular cardiac patches, which are based on
both synthetic and naturally-derived biomaterials [12,15–20]. How-
ever, since electromechanical coupling is essential for the contractile
function of the heart, alternative strategies to restore electrical con-
ductivity at the site of MI should also be investigated [21].
Conductive materials have been incorporated into scaﬀolds to form
biomaterials with enhanced electrical properties for cardiac TE appli-
cations [22–24]. However, some of the engineered conductive scaﬀolds
formed by using electroconductive polymers (e.g. polypyrrole (PPy),
polyaniline (PANi)) or nanomaterials (e.g. carbon nanotubes (CNTs))
may induce cytotoxicity [25,26]. Furthermore, conductive nano-
composite hydrogels may experience a reduction in electrical con-
ductivity under deformation due to increased distances between na-
noparticles in their network [27]. This may limit their in vivo
application due to their inability to propagate electrical impulses
during contraction and expansion of the cardiac tissues.
Another important design criterion for scaﬀolds used for cardiac TE
is the recapitulation of the ﬁbrillar topography of the native myo-
cardium. This is mainly because major components of the cardiac ex-
tracellular matrix (ECM) such as collagen type I and III exist as ﬁbers of
varying diameter and length that mediate cell attachment, migration,
and spreading [28]. In this regard, a variety of microfabrication
Fig. 1. Synthesis and physical properties of electrospun GelMA/Bio-IL cardiopatches. a) Schematic of the electrospinning of GelMA ﬁbrous mats followed by soaking
in Irgacure solution and Bio-IL addition prior to photocrosslinking with UV light for 5 min to form patches. Representative SEM images of patches formed by using
10% (w/v) GelMA with b) 0%, and c) 33% (v/v) Bio-IL. d) The electrical conductivity of cardiopatches fabricated with varying GelMA and Bio-IL concentrations,
showing that the electrical conductivity of patches increased concomitantly when fabricated with higher concentrations of Bio-IL. e) The electroconductive properties
of cardiac patches after incubation in DPBS at 37 °C for 2 and 4 days, which demonstrated that electrical conductivity did not decrease. f) Swelling ratio, g)
degradation rate in collagenase type II solution over time, and h) elastic modulus of fabricated cardiopatches (for swelling ratio and degradation test 10% (w/v)
GelMA was used). Error bars indicate standard error of the means, asterisks mark signiﬁcance levels of p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
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techniques have been developed to engineer scaﬀolds with nano- and
microﬁbrous architectures [29]. Among these, electrospinning is the
most commonly used technique to produce ﬁbrillar scaﬀolds with high
surface area to volume ratios, as well as deﬁned spatial density and
three-dimensional (3D) orientation [30,31]. Lastly, although cardiac
patches hold great potential for the treatment of MI, their integration
with the myocardium by means of sutures or staples may lead to further
trauma and blockage of blood supply, bleeding, and infection. While
diﬀerent alternatives such as medical grade cyanoacrylates [32] and
other bioadhesives [33–35] have been developed to adhere these pat-
ches on the heart, many of these approaches are associated with cyto-
toxicity and high stiﬀness (e.g cyanoacrylates), low adhesion and
structural stability (e.g. ﬁbrin-based bioadhesives), as well as failure to
provide a biomimetic environment that allows for tissue regeneration
[12,36–38]. Therefore, there is an unmet need for engineering highly
biocompatible and electroconductive ﬁbrous scaﬀolds, which can ad-
here strongly to the myocardium to facilitate biointegration without the
need for suturing.
Our group recently introduced a new method to generate highly
biocompatible electroconductive hydrogels based on the conjugation of
a choline-based bio-ionic liquid (Bio-IL) to diﬀerent polymers [39].
Here, we aimed to use Bio-IL to develop electroconductive ﬁbrous
patches that could adhere strongly to the native myocardium to provide
mechanical support and minimize cardiac remodeling following MI. To
form these patches, we electrospun the highly biocompatible gelatin
methacryloyl (GelMA) prepolymer into ﬁbrous patches that were then
chemically conjugated with Bio-IL to impart electroconductivity. We
then characterized the physical, mechanical, electroconductive, and
tissue adhesive properties of engineered GelMA/Bio-IL patches, as well
as their ability to support the growth and function of co-cultures of
cardiomyocytes (CMs) and cardiac ﬁbroblasts (CFs) in vitro. Lastly, we
evaluated the feasibility and safety of in vivo suture-free delivery and
the cardioprotective eﬀect of GelMA/Bio-IL cardiopatches using a
murine model of MI. The intrinsically adhesive and electroconductive
ﬁbrous patches could be used to provide support to the infarcted
myocardium, while also establishing a cell-supportive microenviron-
ment that restores electromechanical coupling and minimizes cardiac
remodeling following MI.
2. Results & discussion
2.1. Physicochemical characterization of GelMA/Bio-IL cardiopatches
Fibrous patches were prepared by ﬁrst electrospinning diﬀerent
concentrations of the GelMA precursor mixed with 1,1,1,3,3,3-hexa-
ﬂuoro-2-propanol (HFIP), onto a static metal collector. Electrospun
patches were then incubated in 1.25% (w/v) Irgacure 2959 in ethanol
for 2 h, followed by direct addition of various concentrations of Bio-IL
and crosslinking via exposure to UV light for 5min (Fig. 1a). Chemical
conjugation of Bio-IL to GelMA was ﬁrst conﬁrmed via proton nuclear
magnetic resonance (1H NMR) as described previously [39]. Brieﬂy, 1H
NMR spectra were obtained for Bio-IL, GelMA prepolymer, photo-
crosslinked GelMA patches, and photocrosslinked GelMA/Bio-IL pat-
ches (Figure S1a-d). We then determined the degree of consumption of
C]C double bonds in methacryloyl groups during free radical poly-
merization, which occurred both due to the crosslinking of GelMA and
the conjugation of Bio-IL to GelMA. Our results showed that
70.2 ± 7.8% of methacryloyl groups were consumed after photo-
crosslinking of GelMA/Bio-IL patch, which was signiﬁcantly higher
than those calculated for pure photocrosslinked GelMA patch
(56.7 ± 9.1%) (Figure S1e). The larger rate of decay of the C]C
double bonds in GelMA/Bio-IL patches represents the chemical con-
jugation of acrylate groups in Bio-IL to methacryloyl groups in GelMA
(Figure S1d).
The native cardiac ECM is comprised of several structural ﬁbrillar
proteins such as collagen and elastin, which range from 10 to several
hundred nanometers in diameter [40]. The formation of biomimetic
ﬁbrous structures plays an important role in the physical characteristics
of TE scaﬀolds, such as their mechanical strength, porosity, and surface
area/volume ratio [41]. Hence, we aimed to characterize the ﬁber to-
pology of GelMA/Bio-IL cardiopatches synthesized with varying con-
centrations of Bio-IL via scanning electron microscopy (SEM)
(Fig. 1b–c, and S2). SEM images showed no signiﬁcant diﬀerences in
the ﬁber diameter when diﬀerent concentrations of Bio-IL were used.
The ﬁber diameter was in the range of 544.0 ± 218.6 nm to
676.7 ± 326.2 nm for the engineered cardiopatches. These results
demonstrated that Bio-IL conjugation does not inﬂuence ﬁber diameter,
enabling the ability to produce scaﬀolds with tunable conductivity
without varying the microstructures.
2.2. Electroconductive properties of GelMA/Bio-IL cardiopatches
The conductivity of the engineered patches was analyzed as pre-
viously described (Figure S3a) [39]. Our results showed that the con-
ductivity of the scaﬀolds could be tuned by varying the concentrations
of both GelMA and Bio-IL (Fig. 1d). For instance, the electrical con-
ductivity of scaﬀolds fabricated with 10% (w/v) GelMA increased from
0.23×10−1 ± 0.02×10−1 S/m to 1.38×10−1 ± 0.12×10−1 S/
m, and 1.90× 10−1 ± 0.18× 10−1 S/m, when the Bio-IL concentra-
tion was increased from 33% to 66%, and 100% (v/v), respectively. As
expected, GelMA patches fabricated with 0% (v/v) Bio-IL did not de-
monstrate any conductivity, as GelMA itself is not inherently con-
ductive. On the other hand, patches fabricated with 66% (v/v) Bio-IL
exhibited an increase in electrical conductivity from
1.38×10−1 ± 0.13×10−1 S/m to 1.77×10−1 ± 0.15×10−1 S/
m, and 3.18×10−1 ± 0.01×10−1 S/m when the GelMA concentra-
tion increased from 10% to 12.5%, and 15% (w/v), respectively.
Though GelMA itself is not inherently conductive, this increase in
conductivity may be attributed to more functional groups available in
the GelMA prepolymer at higher concentration that can react with Bio-
IL. Furthermore, these values are within the range of the electrical
conductivity of the native myocardium, which has been shown to be
between 1.6×10−1 S/m (longitudinally) and 0.05× 10−1 S/m
(transversally) [42].
The conductivity of the scaﬀolds was also characterized after 0, 2,
and 4 days of incubation in Dulbecco's phosphate buﬀered saline
(DPBS) at 37 °C to determine the eﬀect of scaﬀold degradation on
electrical conductivity. These results showed that the conductivity of
GelMA/Bio-IL cardiopatches exhibited no statistically signiﬁcant dif-
ferences after up to 4 days of incubation for all conditions tested
(Fig. 1e). Furthermore, we also evaluated the conductivity of GelMA/
Bio-IL cardiopatches under mechanically strained conditions to de-
termine the eﬀect of scaﬀold deformation on electrical conductivity.
For this, the scaﬀolds were ﬁrst dried for 2 h to retain trace amounts of
moisture and prevent stiﬀening. The presence of moisture led to in-
creased conductivity readings as compared to dried samples (Fig. 1d),
however, allowed samples to be mechanically stretched without
breaking. The samples were then stretched at a strain rate of 20% and
40%, and electrical conductivity was measured in the stretched state as
described before [39]. Our results showed that there were no statisti-
cally signiﬁcant diﬀerences in conductivity of the GelMA/Bio-IL car-
diopatches when stretched up to 40% strain, compared to static con-
ditions (Figure S3b). These results demonstrated that the conductivity
of the scaﬀolds remained unaﬀected following degradation or
stretching, which is critical to maintain a consistent supportive micro-
environment for the excitable phenotypes that comprise the contractile
myocardium.
Here, we demonstrated that systematic variations in the formulation
of GelMA/Bio-IL cardiopatches yielded scaﬀolds with a wide range of
physicochemical properties. Bio-IL conjugation provided GelMA-based
scaﬀolds with highly tunable electrical conductivity (Fig. 1d) without
aﬀecting the ﬁber diameter of the scaﬀolds (Fig. 1b–c). Due to the
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continuous movement of heart due to beating, we aimed to investigate
the conductive properties of these cardiopatches while under mechan-
ical tension, and after up to four days of degradation in vitro. Our results
showed that the conductive properties of the scaﬀolds were not aﬀected
by the degradation (Fig. 1e) or deformation (Figure S3b) of the con-
ductive cardiopatches. Thus, there should not be a signiﬁcant drop in
the conductive properties of our patches while adhered to the heart due
to the contraction or expansion of cardiac tissue. Cardiopatches,
therefore, should support the electrical pathways of the myocardium by
aiding in the propagation of electrical signals throughout all phases of
cardiac cycle. This is in contrast to other composite hydrogels fabri-
cated with conductive nanoparticles where the inter-particle distance
plays a key role in the conductive properties of the scaﬀold [27].
2.3. In vitro swellability and degradation rates of GelMA/Bio-IL
cardiopatches
Excess water intake could potentially compromise the mechanical
and conductive properties of TE scaﬀolds. Hence, we aimed to evaluate
the water uptake capacity of GelMA/Bio-IL cardiopatches. Our results
showed that scaﬀolds fabricated with 10% (w/v) GelMA and varying
Bio-IL concentrations swelled rapidly after 4 h of incubation, with no
signiﬁcant increases in water uptake after 8 and 24 h for all Bio-IL
concentrations (Fig. 1f). Our results also showed that scaﬀolds fabri-
cated with 66% and 100% (v/v) Bio-IL underwent signiﬁcantly higher
swelling when compared to scaﬀolds fabricated with a lower Bio-IL
concentration. This behavior could be explained in part due to the
presence of hydroxyl (eOH) and amine (eNH2) hydrophilic groups in
the Bio-IL structure, which enhances the swelling ratio. There was no
statistically signiﬁcant diﬀerence in the swelling ratio of cardiopatches
fabricated with 66% and 100% Bio-IL after 8 h. However, we observed a
decrease in swelling ratio after 4 h when Bio-IL concentration was in-
creased from 66% to 100% (v/v).. This can be explained, in part, due to
a higher percentage of Bio-IL that is not conjugated to the GelMA
polymer network and is washed out in the ﬁrst 4 h while submerged in
DPBS. Furthermore, scaﬀolds fabricated with 15% (w/v) GelMA
showed a similar trend, with higher swelling ratios obtained at higher
concentrations of Bio-IL (Figure S4).
Following implantation, TE scaﬀolds should biodegrade into non-
toxic byproducts to allow the growth of new autologous tissue [43].
Thus, we aimed to characterize the in vitro enzymatic degradation
proﬁle of GelMA/Bio-IL cardiopatches. Brieﬂy, scaﬀolds were lyophi-
lized and weighed, followed by incubation in DPBS and 5.0 U/mL of
collagenase type II solution at 37 °C for up to 72 h. At the end of this
period, the samples were lyophilized and re-weighed to determine the
changes in dry mass after degradation. The collagenase solution was
replaced daily. Our results showed that the degradation rate increased
concomitantly when the Bio-IL concentration was increased for cardi-
opatches containing 10% (w/v) GelMA (Fig. 1g). For example, our re-
sults show that following 24 h of incubation in collagenase type II so-
lution, cardiopatches demonstrated a degradation rate of
49.65 ± 11.60% and 71.90 ± 4.55% for scaﬀolds fabricated with
33% (v/v) and 100% (v/v) Bio-IL, respectively. In addition, we eval-
uated the in vitro degradation proﬁle of our cardiopatches incubated in
DPBS solution. Our results showed that after 1 day of incubation,
scaﬀolds fabricated using 10% GelMA and 33% (v/v) Bio-IL exhibited
degradation rates corresponding to 25.75% ± 3.57% (Figure S5). At
14 days following incubation, cardiopatches containing 10% (w/v)
GelMA and 33% (v/v) Bio-IL exhibited 45.32 ± 4.27% degradation
(Figure S5). Moreover, the degradation rate increased concomitantly
when the Bio-IL concentration was increased for cardiopatches con-
taining both 10% and 15% (w/v) GelMA. In addition, we did not ob-
serve any statistical diﬀerences between the degradation rate of the
patches fabricated with 10% and 15% (w/v) GelMA after 1 and 14 days.
Both degradation studies performed in DPBS as well as in a collagenase
solution demonstrated that more rapid degradation occurred in
cardiopatches fabricated with a higher concentration of Bio-IL. This
trend could be attributed in part to higher amounts of unconjugated
Bio-IL that were washed out of the hydrogel network.
2.4. Mechanical characterization of GelMA/Bio-IL cardiopatches
Scaﬀolds used for cardiac TE should possess similar mechanical
properties to the native myocardium to prevent mechanical mismatches
that could impair contractile function of native heart [44,45]. Thus, we
evaluated the mechanical properties of scaﬀolds fabricated using
varying concentrations of GelMA and Bio-IL (Fig. 1h and S6a). Our
results showed that the engineered patches exhibited highly tunable
elastic moduli (i.e., 8.76 ± 0.42 kPa to 145.50 ± 4.10 kPa), which
was in the range of the stiﬀness reported for the native myocardium
(∼20–100 kPa) [46,47]. Also, the elastic moduli increased con-
comitantly with increasing GelMA concentrations (Fig. 1h). For in-
stance, the elastic moduli of scaﬀolds fabricated with 33% (v/v) Bio-IL
increased from 19.67 ± 1.70 kPa to 86.23 ± 5.61 kPa, and
110.00 ± 5.56 kPa when the concentration of GelMA increased from
10% to 12.5%, and 15% (w/v), respectively (Fig. 1h). Our results also
showed that the elastic moduli of the scaﬀolds could also be increased
by increasing the concentration of Bio-IL. For instance, the elastic
moduli of scaﬀolds fabricated with 12.5% (w/v) GelMA increased from
86.23 ± 5.61 kPa to 110.45 ± 9.97 kPa, and 134.06 ± 5.06 kPa
when the concentration of Bio-IL was increased from 33% to 66%, and
100% (v/v), respectively (Fig. 1h). This increase in mechanical prop-
erties of the patches may be due to the electrostatic interactions be-
tween the positively charged groups in Bio-IL and the negatively
charged functional groups present in the GelMA polymer. Ionic inter-
actions, such as these, have previously been shown to increase me-
chanical strength in hydrogels [48]. In addition, there might be che-
mical bonding between the Bio-IL and GelMA prepolymer through
photopolymerization, which can also increase the mechanical proper-
ties of the patches. Furthermore, the ultimate strain and ultimate stress
of the scaﬀolds were also shown to vary by changing the concentrations
of both Bio-IL and GelMA (Figure S6). For instance, the ultimate strain
of scaﬀolds with 10% (w/v) GelMA decreased from 84.2 ± 11.46 kPa
to 47.9 ± 8.91 kPa when the concentration of Bio-IL was increased
from 33% to 100% (v/v), respectively (Figure S6b). Moreover, the ul-
timate stress of scaﬀolds fabricated with 33% (v/v) Bio-IL increased
from 31.31 ± 5.18 kPa to 64.59 ± 11.19 kPa, and
89.03 ± 10.41 kPa when the concentration of GelMA was increased
from 10% to 12.5%, and 15% (w/v), respectively (Figure S6c). Taken
together, these results demonstrated the remarkable mechanical tun-
ability of GelMA/Bio-IL cardiopatches, which is highly advantageous
for the engineering of electroconductive scaﬀolds for a variety of TE
and biomedical applications.
Our engineered patches did not exhibit any signiﬁcant increase in
their water uptake capacity after 4 h, and up to 24 h of incubation in
DPBS (Fig. 1f). In addition, our results also showed that the elastic
moduli of GelMA/Bio-IL cardiopatches could be tuned by varying the
concentration of GelMA and Bio-IL, and that the mechanical properties
of the scaﬀolds were within the range of the native human myocardium
(Fig. 1h). These characteristics highlight the remarkable potential of
GelMA/Bio-IL cardiopatches to be used as cardio-supportive devices,
owing to their high electrical conductivity and biocompatibility, con-
trolled swellability and degradability, as well as their biomimetic ﬁ-
brillar topology and mechanical properties.
2.5. Adhesive properties of GelMA/Bio-IL cardiopatches to physiological
tissues
Biomaterials with strong adhesive properties to wet tissues have
emerged as promising strategies for sutureless wound closure following
surgical procedures [49]. In this regard, in our previous studies, we
demonstrated that GelMA-based hydrogels possess high adhesive
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strength to various physiological tissues, while also exhibiting superior
mechanical performance when compared with commercially available
tissue adhesives [37,50]. Here, we aimed to evaluate the adhesive
strength of GelMA/Bio-IL cardiopatches to the native myocardium to
determine their potential for sutureless application following MI. We
used standard wound closure and burst pressure tests from the Amer-
ican Society for Testing and Materials (ASTM), as well as ex vivo ex-
periments using murine cardiac tissue to evaluate the adhesive
properties of our engineered cardiopatches. First, wound closure ex-
periments were carried out to evaluate the adhesive strength of the
scaﬀolds to porcine skin (Figure S7a-b), and murine left ventricular
myocardium (Fig. 2a–c). Wound closure tests showed that the adhe-
siveness of GelMA/Bio-IL cardiopatches to porcine skin increased up to
61.97 ± 2.50 kPa by increasing the concentration of Bio-IL (Figure
S7b). Furthermore, the adhesive strength of scaﬀolds synthesized using
66% and 100% (v/v) Bio-IL was shown to be signiﬁcantly higher than
Fig. 2. Ex vivo Adhesive properties and electrical conductivity of GelMA/Bio-IL cardiopatches. a) Representative image of a GelMA/Bio-IL cardiopatch photo-
crosslinked on explanted rat heart demonstrating the high adhesion of the cardiopatch (red arrows) to cardiac tissues. b) Standard wound closure test using explanted
rat heart as the biological substrate to test the adhesion strength of GelMA/Bio-IL cardiopatches. c) Quantiﬁcation of the adhesion strength exhibited by cardio-
patches fabricated with 10% (w/v) GelMA and varying concentrations of Bio-IL on explanted rat heart. Cardiopatches fabricated with higher concentrations of Bio-IL
demonstrated higher adhesion strength to cardiac tissue. d) Representative images of GelMA/Bio-IL cardiopatch fabricated with 10% (w/v) GelMA and 66% (v/v)
Bio-IL photocrosslinked on the defect site of an explanted rat heart to measure the burst pressure. e) Quantiﬁcation of the burst pressure of GelMA/Bio-IL cardi-
opatches formed with varying concentrations of Bio-IL and photocrosslinked on the defect site of rat heart showed no signiﬁcant diﬀerence when compared to the
burst pressure of a healthy rat heart. f) H&E staining of cardiopatch-tissue interfaces. The tight interface indicates a strong bonding of the GelMA/Bio-IL cardiopatch
to the murine myocardium. The schematic in panel f showing the electrostatic forces between positively charged Bio-IL and negatively charged surface of cardiac
muscle tissue, as well as covalent bonds between methacrylate groups of GelMA and NH2 functional groups in cardiac tissue. These two types of bonding led to strong
adhesion. g) Schematic of ex vivo abdominal tissue placed adjacently on GelMA/Bio-IL cardiopatches fabricated with 10% (w/v) and varying concentrations of Bio-IL
to determine the threshold voltage needed to stimulate both sections of abdominal tissue. h) Quantiﬁcation of the threshold voltage of GelMA/Bio-IL cardiopatches
signiﬁcantly decreased for patches fabricated with 100% (v/v) Bio-IL compared to those fabricated with 33% (v/v) Bio-IL suggesting enhanced electrical properties
with higher concentrations of Bio-IL. Error bars indicate standard error of the means, asterisks mark signiﬁcance levels of p < 0.05 (*). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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the commercial surgical sealants such Coseal™ (19.4 ± 17.3 kPa) and
Evicel® (26.3 ± 4.7 kPa) (Figure S7b). In addition, visual inspection
revealed that scaﬀolds photocrosslinked on the surface of the tissue also
adhered strongly to the native murine myocardium (Fig. 2a). Similarly,
wound closure tests on murine myocardium (Fig. 2b) revealed that the
adhesiveness of GelMA/Bio-IL cardiopatches increased from 5.1 ± 0.4
to 24.89 ± 2.34 kPa as the Bio-IL concentration enhanced from 0% to
100% (v/v) (Fig. 2c). Moreover, the adhesive strength of the engineered
GelMA/Bio-IL cardiopatches was signiﬁcantly higher than other syn-
thesized cardiac sealants such as poloxamine-based hydrogels
(∼17 kPa) [51], and poly (glycerol sebacate)-co-lactic acid (24 kPa)
[52], as well as commercial sealants such as Coseal™ and Evicel®. These
results demonstrated that GelMA/Bio-IL cardiopatches can be readily
applied to the surface of the myocardium and adhere strongly without
the need for sutures or additional tissue adhesives.
We also evaluated the ability of GelMA/Bio-IL cardiopatches to seal
tissue defects under applied pressure using collagen sheets based on a
standard burst pressure test [37,38] (Figure S7c-d), as well as ex vivo
explanted rat hearts (Fig. 2d–e). For burst pressure test using collagen
sheets, we ﬁrst created small defects on sections of the collagen sheet,
which were then sealed by photocrosslinking the cardiopatch on top of
them. We then applied increasing air pressure using a syringe pump
connected to a pressure sensor until failure occurred (Figure S7c). Our
results showed that the burst pressure of GelMA/Bio-IL cardiopatches
adhered onto collagen sheets increased up to 5.36 ± 1.01 kPa by in-
creasing the concentration of Bio-IL (Figure S7d). Moreover, the burst
pressure of patches fabricated with 100% (v/v) Bio-IL was signiﬁcantly
higher than the burst pressure of both Coseal™ (1.7 ± 0.1 kPa) and
Evicel® (1.5 ± 1.0 kPa) (Figure S7d). We also measured the ex vivo
burst pressure of explanted rat heart sealed with our adhesive patches
fabricated with 10% (w/v) GelMA and varying concentrations of Bio-IL
(Fig. 2d and e). For the ex vivo experiments, after sacriﬁcing the ani-
mals, the blood vessels at the base of the heart were sealed with clamps,
and a defect was created near the apex, which was then sealed with the
patch by applying the GelMA/Bio-IL scaﬀold and photocrosslinking for
5min. Our results showed that failure occurred at a pressure of
29.97 ± 5.56 kPa, 32.22 ± 4.38 kPa, and 30.56 ± 4.82 kPa for the
heart sealed by the engineered cardiopatch containing 33%, 66%, and
100% (v/v) Bio-IL, respectively. The burst pressure of these cardiopatch
formulations were similar to the pressure at failure for the intact heart
(i.e., 31.05 ± 0.67 kPa) (Fig. 2e). Furthermore, visual inspection re-
vealed that failure did not occur due to detachment or rupture of the
adhesive patches for all formulations, but due to bursting of the myo-
cardium distal to the defect (Supplementary Video 1). The strong
bonding of GelMA/Bio-IL cardiopatches to the myocardium was further
conﬁrmed via histological evaluation of the interface between the patch
and the tissue (Fig. 2f). Hematoxylin and eosin (H&E) stained micro-
graphs revealed a tight interlocking between the scaﬀold and the
myocardium, which further demonstrated the intrinsic ability of the
scaﬀolds to adhere strongly to the native tissue.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.biomaterials.2019.03.015.
Standard wound closure (Fig. 2c) and burst pressure (Fig. 2e) tests
demonstrated the high adhesive strength of the scaﬀolds, which was
superior to commercial tissue adhesives, as well as other proposed
bioadhesives, such as a hydrophobic light activated heart glue [53].
These observations were further conﬁrmed via histological evaluation,
which revealed the tight interlocking at the interface between the
patches and the myocardium (Fig. 2f). GelMA has been previously re-
ported as a suitable material to obtain strong adhesion to wet tissues
[37]. This is due to the covalent bonds formed between methacrylate
groups of GelMA and amine groups of tissue during photocrosslinking
[54]. Thus, once photocrosslinking has been completed, the anterior
side of our cardiopatches will not adhere to the pericardial sac. In ad-
dition, GelMA/Bio-IL cardiopatches demonstrated signiﬁcantly stronger
adhesion to cardiac tissue when fabricated with higher concentrations
of Bio-IL. This can be attributed to electrostatic interactions between
the negatively charged surface of cardiac tissue (carboxyl group) and
our positively charged choline-based Bio-IL [33,55–57]. In fact, the
strong adhesion between GelMA/Bio-IL patches and tissues can be at-
tributed to the formation of two diﬀerent types of chemical bonds:
covalent bonds between GelMA and tissue, and ionic bonds between
Bio-IL and tissue (schematic shown in Fig. 2f).
Recent studies have also reported the development of adhesive and
conductive cardiac patches based on the incorporation of gold-na-
norods [12] and dopamine [58] in synthetic polymer networks. While
these suture-free strategies greatly enhance the clinical translation of
bioengineered cardiopatches by minimizing the risk of additional tissue
damage, they may not lead to tissue repair and regeneration due to the
absence of cell binding sites in the polymer network. In addition, pre-
vious groups have demonstrated the intrinsic potential of GelMA-based
scaﬀolds to act as potent angiogenic niches [59]. Therefore, in contrast
to alternative strategies, GelMA/Bio-IL cardiopatches could also act as
proangiogenic patches that could help salvage the ischemic myo-
cardium during the early stages following MI [60]. These scaﬀolds
could also be used as a supportive layer that can minimize the risk of
free wall rupture during the later stages of cardiac remodeling [61],
owing to their strong tissue-adhesiveness biomimetic mechanical
properties.
2.6. Evaluation of GelMA/Bio-IL cardiopatches capability to restore
impulse propagation across severed striated muscle ex vivo
Electroconductive scaﬀolds could be used to restore electrical
communication between excitable cell types to preserve the function-
ality of the tissue. Thus, we evaluated the ability of GelMA/Bio-IL
cardiopatches to restore impulse propagation between two pieces of
skeletal muscle ex vivo. For this, the rectus abdominis muscles of Wistar
rats were explanted post-mortem, cut into square pieces, and placed
3mm apart from each other on top of the scaﬀolds (Fig. 2g). Pulsed
direct current test runs were conducted by applying 50ms square pulses
at increasing frequencies, using short platinum wires that were placed
on one of the two samples. Muscle contraction was visually assessed on
the opposite sample and the threshold voltage was recorded (Supple-
mentary Video 2). As expected, our results showed that scaﬀolds con-
taining higher concentrations of Bio-IL exhibited comparatively lower
threshold voltages as compared to GelMA patches without Bio-IL
(Fig. 2h). Therefore, the engineered GelMA/Bio-IL cardiopatches could
be used to restore the propagation of electrical impulses and preserve
the functionality of excitable tissues damaged by trauma or disease.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.biomaterials.2019.03.015.
2.7. In vitro contractile activity and phenotype of CMs cultured on GelMA/
Bio-IL cardiopatches
One of the most important aspects in the design of TE scaﬀolds is the
accurate recapitulation of the diﬀerent stimuli that modulate cell fate.
CMs are electroactive cells that rely on electrical stimuli for main-
taining tissue homeostasis and function [62]. Therefore, electro-
conductive scaﬀolds hold great potential for cardiac TE since they can
promote the propagation of electrical impulses and enhance electro-
mechanical coupling of CMs in vitro [63]. Here, we aimed to evaluate
the ability of GelMA/Bio-IL cardiopatches to support the growth and
the contractile function of co-cultures of freshly-isolated CMs and CFs.
For this, primary CMs and CFs (2:1 ratio) were drop seeded on top of
GelMA/Bio-IL scaﬀolds fabricated using diﬀerent concentrations of Bio-
IL. Cell viability and proliferation were evaluated using a commercial
Live/Dead assay (Fig. 3a) and ﬂuorescent F-actin/cell nuclei staining
(Fig. 3b), respectively. The results demonstrated that the viability of
CMs/CFs remained> 90% up to day 7 post-seeding for all conditions
tested (Fig. 3c). In addition, quantitative analysis of ﬂuorescent images
B.W. Walker, et al. Biomaterials 207 (2019) 89–101
94
Fig. 3. 2D co-cultures of CMs and CFs on GelMA/Bio-IL cardiopatches. The in vitro cytocompatibility of the engineered cardiopatches was evaluated using 2D co-
cultures of freshly isolated CMs and CFs (ratio 2:1) growing on cardiopatches fabricated with diﬀerent concentrations of Bio-IL. a) Representative Live/Dead images
of CMs/CFs growing on patches containing 0% and 66% (v/v) Bio-IL at day 7 post-seeding. b) Representative actin/DAPI images of CMs/CFs growing on patches
fabricated with 0% and 66% (v/v) Bio-IL at day 7 post-seeding (Scale bar= 200 μm). Bar graphs showing the quantiﬁcation of c) cell viability, and d) metabolic
activity of 2D co-cultures of CMs/CFs at days 1, 4, and 7 post-seeding, growing on cardiopatches engineered with diﬀerent concentrations of Bio-IL. e)
Characterization of the beating frequency (beats/min) of CMs/CFs throughout 7 days of culture growing on cardiopatches fabricated with varying concentrations of
Bio-IL. Representative immunoﬂuorescent images of CMs/CFs at day 7 post-seeding growing on the surface of patches containing f) 0%, and g) 66% (v/v) Bio-IL
(green: sarcomeric α-actinin, red: connexin 43, blue: DAPI) (Scale bar= 50 μm). Quantiﬁcation of the relative levels of expression (i.e., intensity of ﬂuorescence) of
h) connexin 43, and i) sarcomeric α-actinin in co-cultures of CMs/CFs on engineered patches at day 7 post-seeding. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the Web version of this article.)
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revealed that GelMA/Bio-IL scaﬀolds support the proliferation of CFs,
which led to increasingly higher number of cells throughout the dura-
tion of the experiment (Figure S8). The metabolic activity of cells
growing on GelMA/Bio-IL cardiopatches was signiﬁcantly higher than
those growing on GelMA controls (Fig. 3d). We also evaluated the
contractile activity of CMs seeded on GelMA/Bio-IL scaﬀolds. For this,
cell-seeded scaﬀolds were imaged daily using an inverted microscope
equipped with a CCD camera and a temperature-controlled chamber at
37 °C. The beating frequency (beats/min, BPM) of the CMs was calcu-
lated from digitized video-recorded sequences using a custom MATLAB
program. Our results showed that cells grown on cardiopatches con-
taining 33% and 66% (v/v) Bio-IL exhibited a comparatively more ro-
bust contractile behavior, when compared to pristine GelMA and
GelMA with 100% (v/v) Bio-IL scaﬀolds (Fig. 3e). Moreover, cells
grown on GelMA cardiopatches fabricated with 33% and 66% (v/v)
Bio-IL exhibited observable contractility at day 7 post-seeding, and
signiﬁcantly higher beating frequencies (157.143 ± 1.742 BPM and
196.524 ± 1.018 BPM, respectively) than those growing on pristine
GelMA patch and GelMA with 100% (v/v) Bio-IL cardiopatches
(104.643 ± 5.845 BPM and 110.210 ± 7.360 BPM, respectively)
(Fig. 3e). The lower contractile activity of the cells grown on GelMA
patches (Supplementary Video 3) can be due to the non-conductivity of
the scaﬀold with no Bio-IL. On the other hand, when 100% (v/v) Bio-IL
was used, the excess amount of Bio-IL might cover cell binding sites
available on GelMA prepolymer, leading to lower cell attachment and
contractile activity (Supplementary Video 5). Highest beating fre-
quency was observed for the cells cultured on cardiopatches with 66%
(v/v) Bio-IL (Supplementary Video 4).
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.biomaterials.2019.03.015.
The contractile function of the myocardium is established by a
complex network of interconnected cells that communicate via gap
junction proteins termed connexin, which mediate the propagation of
electrical impulses [64]. Here, we evaluated the expression of pheno-
typic cardiac markers in cells grown on pristine GelMA scaﬀolds and
GelMA cardiopatches containing 66% (v/v) Bio-IL, via immuno-
ﬂuorescent staining (IFS) against sarcomeric α-actinin (SAA) and con-
nexin 43 (Cxs43). Representative ﬂuorescent images revealed that cells
seeded on the scaﬀolds self-organized in clusters of contracting CMs,
which were attached to a layer of CFs proliferating on the surface of the
scaﬀolds (Fig. 3f and g). Our results also showed that cells grown on
GelMA cardiopatches with 66% (v/v) Bio-IL exhibited signiﬁcantly
higher levels of Cxs43 expression, located mainly between the borders
of the CFs, as compared to pristine GelMA patches (Fig. 3h). These
observations suggest that GelMA/Bio-IL cardiopatches could aid in the
propagation of electrical impulses between isolated cells to enhance the
tissue-level functionality and beating of cardiac constructs.
The native myocardium is an electroactive tissue that can transfer
electrical impulses that enable the synchronous contraction of the CMs,
which in turn carry out the pump function of the heart. Our results
demonstrated that GelMA/Bio-IL cardiopatches could eﬀectively pro-
mote the growth and function (Fig. 3) of co-cultures of CMs and CFs in
vitro. Bio-IL conjugation led to a comparatively better contractile proﬁle
than pristine GelMA scaﬀolds, as demonstrated by the increased me-
tabolic activity (Fig. 3d) and enhanced beating frequency (Fig. 3e)
observed for conductive cardiopatches. In the context of cardiac elec-
trophysiology, the propagation of electrical impulses is mediated via
connexin proteins such as Cxs43, which enable heterocellular electrical
coupling between CMs and CFs [65,66]. Moreover, previous studies
have showed that Cxs43-mediated CF coupling in vitro could enable
synchronous spontaneous contraction in isolated CMs located up to
300 μm apart [67]. In this regard, IFS (Fig. 3f and g) showed that CFs
growing on conductive scaﬀolds exhibited signiﬁcantly higher levels of
expression of Cxs43 when compared to GelMA-controls (Fig. 3h).
Moreover, positive ﬂuorescence against this gap junction protein was
mainly located to the borders between the proliferating layer of CFs
(Fig. 3g). These observations suggested that the conductive properties
of GelMA/Bio-IL scaﬀolds promoted the electromechanical coupling of
isolated CMs through the upregulation of Cxs43 in CFs. Furthermore,
the disruption of electrical communication between cardiac cells has
been shown to contribute to the generation of arrhythmias in ﬁbrotic
hearts in vivo and hinder the contractile function of TE cardiac con-
structs [67]. Therefore, Bio-IL conjugation could be used to aid in the
rapid propagation of electrical impulses across heterocellular TE scaf-
folds, and lead to enhanced tissue-level functionality both in vitro and in
vivo.
2.8. In vivo application of GelMA/Bio-IL cardiopatches using a murine
model of MI
A series of structural and functional abnormalities occur after the
onset of MI, which compromise the contractile function of the heart and
could potentially lead to free wall rupture and death [68]. Electrospun
ﬁbrous patches have shown great potential to be used as cardio-sup-
portive devices to help minimize the formation of non-contractile scar
tissue and thinning of the infarcted myocardium [69,70]. However, the
delivery of conductive scaﬀolds to the myocardium presents several
risks that could potentially lead to impaired cardiac function or fatal
arrhythmias [71]. Thus, in this study, we evaluated the feasibility,
safety and in vivo functionality of GelMA/Bio-IL cardiopatches using a
murine model of MI via permanent ligation of the left anterior des-
cending (LAD) coronary artery (Fig. 4ai–iv). All infarcts were conﬁrmed
via blanching of the myocardium distal to the site of ligation. Following
the induction of MI, animals were divided into three treatment groups:
sham, GelMA control, and GelMA/Bio-IL; and followed for a period of 3
weeks to allow for cardiac remodeling. We used scaﬀolds fabricated
with 10% (w/v) GelMA and 33% (v/v) Bio-IL for the treatment group
that received conductive cardiopatches. At the end of this period, the
animals were sacriﬁced, and the hearts were excised and processed for
histological evaluation using Masson's trichrome and IFS against the
cardiac markers SAA and Cxs43. Our results showed strong adhesion of
both GelMA (Fig. 4b) and GelMA/Bio-IL (Fig. 4c) patches to the myo-
cardial tissue after 3 weeks. Also, tissue ingrowth inside the scaﬀolds
was observed for both GelMA and GelMA/Bio-IL samples. In addition,
the cardiopatches were intact on the surface of the myocardium 21 days
post implantation. Further, it was found that the sham controls ex-
hibited signiﬁcant thinning of the myocardium with a large aneurysmal
section on the LV (Fig. 4di). The infarcted area exhibited a marked
reduction in the expression of both SAA and Cxs43, which was in-
dicative of extensive CM death and the appearance of non-contractile
scar tissue (Fig. 4dii-iii). In contrast, the animals receiving both the
GelMA (Fig. 4ei) and GelMA/Bio-IL (Fig. 4ﬁ) cardiopatches showed
comparatively less ventricular wall thinning and no apparent aneurysm
at the site of MI after 3 weeks. Furthermore, the expression of pheno-
typic cardiac markers was maintained throughout the site of MI, which
was indicative of the preservation of a fully functional myocardium for
both hearts treated with GelMA scaﬀolds (Figure eii-iii) and GelMA/
Bio-IL cardiopatches (Fig. 4ﬁi-iii). These results suggested that both
GelMA-based patches could establish a cell-supportive microenviron-
ment that prevented the remodeling of the myocardium at the site of MI
and preserve normal tissue architecture. Furthermore, the expression of
characteristic phenotypic markers SAA and Cxs43 was indicative of the
preservation of viable myocardium and the maintenance of normal
cardiac function.
Following MI, cardiac remodeling triggers a series of molecular and
cellular changes that manifest clinically as changes in ventricular wall
thickness and the appearance of ﬁbrotic scar tissue [61]. In recent
years, electrospun scaﬀolds have shown great potential to be used as
cardio-supportive devices, which can help minimize the formation of
non-contractile scar tissue and thinning of the ventricular wall fol-
lowing MI [70]. Here, we evaluated the feasibility and safety of in vivo
delivery as well as the cardioprotective potential of GelMA/Bio-IL
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Fig. 4. In vivo evaluation of GelMA/Bio-IL cardiopatches using a murine model of MI. Experimental MIs were induced via permanent ligation of the LAD coronary
artery. a) Representative images showing: a-i) LAD ligation (white circle), a-ii) photocrosslinking of cardiopatches (white arrows) using UV light, a-iii) photo-
crosslinked cardiopatch on the heart, and a-iv) excised whole heart with cardiopatch distal to the site of LAD ligation after 21 days. Representative Masson's
trichrome stained images from the interface between tissue and b) GelMA and c) GelMA/Bio-IL cardiopatches after 21 days (Scale bar= 400 μm). Representative
Masson's trichrome and ﬂuorescent stained images of excised hearts showing the location of the MIs in di-iii) untreated animal (sham), and animals treated with ei-
iii) pristine GelMA patches, and ﬁ-iii) GelMA/Bio-IL cardiopatches.
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cardiopatches using a murine model of MI via permanent LAD ligation
(Fig. 4ai-iv). Histological evaluation revealed that the hearts treated
with both GelMA and GelMA/Bio-IL patches exhibited minimal tissue
remodeling and LV wall thinning, when compared to untreated animals
(Fig. 4d–f). These observations suggested that the supportive function
of both GelMA and GelMA/Bio-IL scaﬀolds could potentially ameliorate
LV wall stress and preserve normal tissue architecture. These results
were in accordance to previous studies showing that cardio-supportive
devices with ECM-like properties can mediate endogenous repair me-
chanisms to improve heart function [72]. Moreover, these studies also
showed that the attenuation of pathological cardiac remodeling oc-
curred mainly due to architectural and compositional cues that po-
tentiated tissue regeneration, independent of scaﬀold electro-
conductivity.
Our results suggested that GelMA/Bio-IL scaﬀolds yielded tissue
constructs with comparatively better in vitro functionality, which could
be due in part to enhanced electromechanical coupling via upregulation
of the gap junction protein Cxs43. Moreover, in vivo evaluation showed
that both conductive and non-conductive GelMA-based scaﬀolds led to
the preservation of normal tissue architecture by minimizing cardiac
remodeling after MI. These observations could be explained in part due
to the complex interplay of diﬀerent bioactive cues that are normally
present in vivo [73–76], which were not replicated in our experiments in
vitro. Furthermore, these results demonstrated that cardiac remodeling
could be eﬀectively prevented using acellular scaﬀolds without the
need for exogenous cytokines or growth factors, which is highly ad-
vantageous for the clinical translation of these scaﬀolds. For instance,
Montgomery et al. recently reported a microfabricated injectable scaf-
fold that could be used to deliver viable and functional CMs to the site
of MI [77]. Although the scaﬀolds could be delivered through a mini-
mally invasive procedure and signiﬁcantly improved cardiac function
following MI, both adult and stem cell-based strategies for the treat-
ment of MI often shown highly heterogenous outcomes and poor clin-
ical translation [8,9]. Moreover, one of the most relevant characteristics
of GelMA/Bio-IL cardiopatches was their high adhesive strength to the
beating myocardium after photocrosslinking, even in the presence of
blood (Fig. 4aiii-iv). Recently, Lang et al. reported the development of
blood-resistant and light-activated surgical glue that could be used to
seal cardiac wall defects in large animal models [78]. Although this
bioadhesive could be used by itself to form an on-demand hemostatic
seal or in combination with a patch, GelMA/Bio-IL cardiopatches at-
tached strongly to the native tissue without the need for additional
adhesives or sutures. This also allowed the establishment of a tight
interface and enhance the interlocking between GelMA ﬁbers from the
ECM-like ﬁbrous patch and the myocardium, which is characteristic of
strong tissue adhesives [34,79]. In addition, cardiopatches photo-
crosslinked on the surface of rat hearts did not exhibit signiﬁcant
changes in size due to water uptake of the scaﬀolds (Fig. 4aiii-iv). This
demonstrates that swelling of our engineered cardiopatches would not
signiﬁcantly compress cardiac tissues in vivo.
In situ photocrosslinking of cardiopatches on the beating heart could
possibly lead to systemic dissemination of unreacted components and
thus, trigger toxic or inﬂammatory responses that could not be eval-
uated in vitro. Our preliminary in vivo experiments conﬁrmed that our
electroconductive patches could be safely administered on the myo-
cardium via in situ photopolymerization and did not induce any cyto-
toxicity. In addition, the heart is a highly dynamic organ and the pre-
sence of blood and other ﬂuids, as well as cardiac beating could greatly
impair the adherence of the patches to the myocardium in vivo. Our in
vivo results here demonstrated that the engineered patches exhibited
high adhesion to the native murine myocardium without the need for
suturing. Lastly, although the electroconductive and mechanical prop-
erties of the patches were tuned to mimic the native tissue, the delivery
of a scaﬀold with these features to the myocardium could potentially
impair cardiac function or even lead to fatal arrhythmias. Therefore,
our current study aimed on evaluating the safety of in vivo delivery of
Bio-IL functionalized patches before assessing the therapeutic eﬀects of
this strategy. Our future study will focus on evaluating heart function
after applying the electroconductive patches using echocardiography,
as well as studying the molecular and cellular mechanisms that could be
selectively triggered by the delivery of an electroconductive scaﬀold to
the site of MI.
3. Conclusion
In this work, we introduced a new class of adhesive and electro-
conductive cardiopatches for the treatment of MI. Cardiopatches were
synthesized from two naturally derived sources: GelMA, and a highly
electroconductive and biocompatible choline-based Bio-IL. The me-
chanical and conductive properties of these cardiopatches were shown
to be readily tunable by varying the concentrations of GelMA and Bio-
IL. Bio-IL functionalization rendered cardiopatches with high adhesive
strength to the native myocardium, which was comparatively superior
to commercially available adhesives, such as Coseal™ and Evicel®.
GelMA/Bio-IL cardiopatches could support the growth and function of
primary CMs and CFs seeded on the surface of the scaﬀolds in vitro. Our
results showed that electroconductive scaﬀolds exhibited compara-
tively better contractile proﬁles than pristine controls due to the
overexpression of the gap junction protein Cxn43. GelMA/Bio-IL car-
diopatches could be readily attached to the epicardial surface of the
heart via photocrosslinking, which eliminates the need for sutures that
could lead to further tissue trauma. Furthermore, histological assess-
ment was indicative of comparatively lower thinning of the ventricular
wall 3 weeks after induction of experimental MI. However, further
experiments focusing on the evaluation of cardiac function following
MI are needed to elucidate the cardioprotective eﬃcacy of this strategy.
In addition, the long-term eﬀects of the epicardial application of the
cardiopatches and the potential development of co-morbidities such as
constrictive pericarditis, arrhythmias and other systemic syndromes
should also be evaluated. GelMA/Bio-IL cardiopatches hold great po-
tential to be used as scaﬀolds to provide mechanical stabilization to the
injured myocardium and to restore electromechanical coupling at the
site of MI.
4. Experimental section
4.1. Cardiopatch fabrication
Porcine GelMA was synthesized as described previously [80]. A
prepolymer solution was then prepared by mixing 10, 12.5, and 15%
(w/v) of GelMA in hexaﬂuoroisopropanol (HFIP) (Sigma-Aldrich), and
placed in a syringe with a 27G needle. The prepolymer solution was
then pumped out of the syringe at a rate of 1mL/h. A high voltage
power source (Glassman High Voltage, Inc., Series EH) was attached to
the needle of the syringe, and to a metal collector that the GelMA
polymer was spun on, creating a ﬁbrous mat. Fibrous scaﬀolds were
then removed from the collector plate and placed in a vacuum to re-
move any remaining solvent. Scaﬀolds were then placed in a solution
bath containing 1.25% (w/v) photoinitiator Irgacure 2959 (Sigma-Al-
drich) in ethanol. Bio-IL was also synthesized using the previously
discussed methodology [39]. Four concentrations of Bio-IL in water
were prepared including 0, 33, 66, and 100% (v/v). Scaﬀolds were
placed in a refrigerator to prevent the dissolving of GelMA ﬁbers in Bio-
IL/water solution. A volume of 1mL Bio-IL was then placed on the
surface of GelMA ﬁbrous scaﬀolds and immediately crosslinked using
UV irradiation for 300 s on each side of the scaﬀold.
4.2. 1H NMR characterization
1H NMR analysis was performed using a Varian Inova-500 NMR
spectrometer. 1H NMR spectra were obtained for a choline-based Bio-IL
prepolymer, GelMA, prepolymer, GelMA ﬁbers after UV
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photocrosslinking, and Bio-IL/GelMA cardiopatches. Methacrylated
groups were identiﬁed due to the presence of peak values at δ=5.3,
and 5.7 ppm. The decreasing rate for the C]C double bond signals
−∂ =
∂( )C Ct( ) in methacrylate group of GelMA was associated with the
extent of crosslinking of cardiopatch, as well as conjugation of GelMA
to Bio-IL. This area decrease was calculated using the following equa-
tion:
⎜ ⎟= ⎛
⎝
− ⎞
⎠
×PA PA
PA
Decay of methacrylate group (%) 100%b a
b
where PAb, and PAa represent the peak areas of methacrylated groups
before and after photocrosslinking, respectively. Accordingly, PAb – PAa
corresponds to the concentration of methacrylated groups consumed in
the photocrosslinking process. ACD/Spectrus NMR analysis software
were used to integrate the area under the peaks and all the data was
analyzed with respect to phenyl group peaks at δ=6.5–7.5 ppm.
4.3. Scanning electron microscopy (SEM) analysis
The diameter and morphology of the electrospun nanoﬁbrous sheets
were examined by SEM (Hitachi S-4800, Japan). Prior to imaging, the
samples were ﬁxed in 2% osmium tetroxide (OsO4, Fisher Scientiﬁc).
The scaﬀolds were then washed three times with DPBS each for 5min,
followed by dehydration in graded ethanol series (i.e., 30, 50, 70, 95,
and 100% v/v) each for 10min. Next, samples were dried at critical
point with a Tousimis critical point dryer. After drying, the scaﬀolds
were sputter coated with gold/palladium (6 μm). The obtained images
were processed by ImageJ software to determine the average ﬁber
diameter sizes (50 arbitrary ﬁbers per each group).
4.4. In vitro evaluation of conductivity
Cardiopatches were photocrosslinked with UV irradiation for 300 s
on each side and allowed to dry for 24 h. Once dried, conductivity
analysis was performed using a two-probe electrical station connected
to a Semiconductor Parameter analyzer, as previously described (Figure
S3a) [81]. The results were then analyzed to determine the electrical
conductivity of cardiopatches. Cardiopatches were also examined for
conductivity following degradation in DPBS at 37 °C for a period of 0, 2,
and 4 d. Samples were removed from DPBS and allowed to dry for 24 h.
Electrical conductivity was then measured using the same protocol to
measure electrical conductivity in samples that had not degraded. The
conductivity of cardiopatches was also determined using methods
previously described [81]. Cardiopatches were also examined for con-
ductivity under stretched conditions. Brieﬂy, cardiopatches were fab-
ricated using the same method as above, but were dried for only 2 h to
prevent brittleness. The trace amount of moisture led to increased
conductivity readings, however, allowed samples to be mechanically
stretched without breaking. Samples were stretched at a strain of 0, 20,
and 40% and conductivity was measured using the same method as
above. At least 5 samples were tested for each condition.
4.5. Swelling ratio measurements
Cardiopatches of varying GelMA and Bio-IL concentrations were
synthesized as described previously and cut into small pieces. The small
pieces were then lyophilized, weighed, and placed in DPBS at 37 °C. At
designated time points (4, 8, 24 h), samples were removed and weighed
again after immersion. The swelling of the samples was calculated as
the ratio of the swelled mass to the mass of the lyophilized sample.
4.6. In vitro degradation test
Cardiopatches were synthesized as previously described, cut into
small square sections, and lyophilized overnight. Samples were
weighed and placed in 1.5mL tubes of 1mL DPBS with 5.0 U/mL col-
lagenase type II, and incubated at 37 °C for up to 72 h. The collagenase
solution was refreshed every 24 h. At designated points (after 6, 12, 24,
48, and 72 h), the collagenase solution was removed, and samples were
lyophilized for 24 h and weighed. The percentage of degradation (D %)
of the cardiac patches was calculated using the below equation:
= − ×D % W W
W
100%i t
i
where Wi is the initial dry weight of the patch, and Wt is the dry weight
after time t.
4.7. Mechanical testing
Tensile test was performed on cardiac patches using an Instron 5944
mechanical tester using method previously described [81]. Brieﬂy,
cardiopatches with varying polymer and Bio-IL concentration were
synthesized and cut into rectangular pieces (length: 12.0 mm, width:
5.0 mm). Cardiopatches were then stretched at a rate of 1 mm/min
until rupture. The load (N) and tensile strain (mm) values were re-
corded using the accompanying Bluehill 3 software. Elastic moduli of
the fabricated cardiopatches were obtained by measuring the slope of
the stress-strain curves (0.1-0.3 mm/mm strain). At least 5 samples
were tested for each condition.
4.8. Wound closure test
Wound closure tests were performed using a modiﬁed ASTM F2458-
05 to determine the adhesive strength based on the previously ex-
plained procedures [38,50,82]. Porcine skin and rat myocardium wet
tissues were used as substrates. Brieﬂy, samples of the biological sub-
strate were cut into 40×20mm pieces with a thickness of approxi-
mately 5mm. The substrate was immersed in DPBS to prevent drying.
Tissue samples were then glued with cyanoacrylate adhesive onto glass
slides. Two sections of the substrate were then placed against each
other, and a cardiopatch was photocrosslinked for 300 s over the tissues
to glue them together. An Instron mechanical tester was used to mea-
sure the maximum adhesive strength at the point of patch failure.
4.9. Burst pressure test
Burst pressure adhesion test was performed using a modiﬁed ASTM
F2392-04 for determining the sealing strength of a biomaterial.
Collagen sheets were used as substrates. First, the collagen sheet was
soaked in DPBS for 1 h and placed between two Teﬂon plates and
placed into a custom-designed burst pressure apparatus. A 3mm defect
was then created into the substrate using a surgical blade.
Cardiopatches were then fabricated and photocrosslinked on the defect
site, and air pressure was increased until patch failure (Figure S7c).
A modiﬁed ex vivo burst pressure test was conducted using cardio-
patches photocrosslinked on freshly explanted rat hearts according to
previously published reports [33]. Brieﬂy, an air tube was fed through
the top of excised rat hearts into the LV, and a defect was created on the
myocardial wall of the LV using a surgical blade (2mm). Cardiopatches
were photocrosslinked onto the defect site. Rat hearts were then placed
in a beaker containing water and air pressure was increased in the LV
until patch failure.
4.10. Ex vivo evaluation of electrical conductivity
Adult female Wistar rats were provided by the Institutional Animal
Care and Use Committee (ICAUC) at Northeastern University (Boston,
MA, USA). All experiments were performed in accordance with relevant
guidelines and regulations. Immediately after euthanasia, the rectus
abdominus tissue was removed from Wistar rats and placed in DPBS.
The rectus abdominus was cut into small square pieces and placed
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adjacently with a 3mm gap on cardiopatches with varying Bio-IL
concentration. 50ms square pulses of direct current were applied to the
tissue using an Agilent wave generator (Agilent 33220A). The electrical
stimulation was applied to one piece of abdominal tissue using short
platinum wires with 0.25mm diameter and 99.9% trace metal basis,
bought from Sigma-Aldrich (MO, USA). The threshold was measured by
increasing voltage applied to one section of abdominal tissue and ob-
serving the lowest voltage at which the neighboring section of tissue
contracted.
4.11. Surface seeding of primary CMs and CFs on GelMA/Bio-IL
cardiopatches and in vitro evaluation
A thin layer of 10% (w/v) GelMA was electrospun onto
0.8×0.8 cm glass slides, coated with 3-(trimethoxysilyl) propyl me-
thacrylate (TMSPMA). The glass slides were then soaked in 1.25% (w/
v) Irgacure 2959 solution for 1 h, and kept at −80 °C for 1min. A
conductive layer was then formed on top of the electrospun GelMA by
pipetting a 50-μl drop of Bio-IL at diﬀerent concentrations (i.e., 0%,
33%, 66%, and 100% (v/v)), followed by UV-initiated photo-
crosslinking for 300 s. The samples were incubated overnight in
Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented with 10%
Nu-Serum growth supplement, and 1% penicillin/streptomycin.
Primary CMs and CFs were isolated from neonatal rat hearts as de-
scribed previously [39]. Co-cultures of CMs/CFs were then seeded at a
ratio of 2:1 on top of the scaﬀolds at a density of 2×105 cells/cm2 and
maintained at 37 °C, in a 5% CO2 humidiﬁed atmosphere for up to 7
days. Cell viability, and metabolic activity were determined at days 1,
4, and 7 post-seeding as described in our previous publication [39]. IFS
against cardiac markers SAA and Cxs43 was carried out as described
previously [39]. In addition, rhodamine-phalloidin (Alexa Fluor 488-
labeled or 594-labeled, Invitrogen) and DAPI (4',6-diamidino-2-phe-
nylindole) (Sigma Aldrich) staining was perfomed to image F-actin and
cell nuclei of cells seeded on the surface of cardiopatches. For beating
characterization, CM contractile properties on cardiopatches were as-
sessed using movies taken with a video camera attached to a micro-
scope over 7 days of culture. To quantify the beat frequency (number of
beats/min), videos taken from 3 selected spots of at least 3 individual
samples were analyzed with a custom-written Matlab code.
4.12. In vivo evaluation of biosafety and cardioprotective potential of
electrospun scaﬀolds
All experiments were performed according to the protocol approved
by the IACUC at Northeastern University. Experimental MI was induced
via permanent ligation of the LAD as described previously [83]. Im-
mediately after induction of MI, the scaﬀolds were delivered to the
surface of the left ventricle, distal to the site of MI, and photo-
crosslinked for 300 s using UV light. To remove any unreacted Bio-IL,
saline was pipetted to the surface of cardiopatches and excess liquid
was collected using a gauze pad. Animals were divided into three
groups: sham (control), pristine GelMA patches (i.e., 10% (w/v)
GelMA), and GelMA/Bio-IL patches (i.e., 33% (v/v) Bio-IL and 10% (w/
v) GelMA). There were 3 animals per group. Following administration
of the treatments, the animals were allowed to recover after anatomical
wound closure and followed for a period of 3 weeks. After this period,
the animals were euthanized, and the hearts were removed and pro-
cessed for histological evaluation and IFS as described previously [39].
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